OBJECTIVE
The study was designed to test the feasibility that lower genital tract cytology is a compatible medium for robust germ line genetic analyses.
METHOD
BRCA1 and/or BRCA2 gene mutational analysis was done on DNA isolated from liquid-based cervical or vaginal cytology taken from 17 consenting women (age 29-65 years) who previously had genetic counseling followed by BRACAnalysis (Myriad Genetics, Salt Lake City, UT) blood analyses. Eleven women had known mutations in either BRCA1 or BRCA2 (cases) and six had no identified mutations (controls) on entry into the study. Anonymized cytology samples were sent to Myriad Genetics with a request for testing that was limited to the degree of genomic testing previously done on the blood samples.
RESULTS
One cervicovaginal specimen from a test-positive woman had inadequate cellular content that precluded gene sequencing and therefore was excluded from this analysis. For the 16 women with adequate cytologic specimens, there was 100% concordance for BRCA mutation test results between blood and genital tract cytology (kappa = 1.0; 95% confidence interval, 0.51-1.0).
CONCLUSION
We have shown the feasibility of using liquid-based genital tract cytology as an alternative biospecimen to blood for germ line genetic analysis using a clinical approved assay. It needs to be emphasized that any type of testing for BRCA1 or BRCA2 mutation genotype should only be done in the setting of pretest and posttest counseling.
[1]
B. Ward,et al.
Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
,
2002,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2]
S J Bernstein,et al.
Liquid-based cervical cytologic smear study and conventional Papanicolaou smears: a metaanalysis of prospective studies comparing cytologic diagnosis and sample adequacy.
,
2001,
American journal of obstetrics and gynecology.
[3]
M. Schiffman,et al.
Comparison of three management strategies for patients with atypical squamous cells of undetermined significance: baseline results from a randomized trial.
,
2001,
Journal of the National Cancer Institute.
[4]
A. Maitra,et al.
Molecular Papanicolaou tests in the twenty-first century: molecular analyses with fluid-based Papanicolaou technology.
,
2000,
American journal of obstetrics and gynecology.
[5]
S. Cummings,et al.
Sequence analysis of BRCA1 and BRCA2: correlation of mutations with family history and ovarian cancer risk.
,
1998,
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.